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ABSTRACT: A synthesis strategy for the swift generation of 4”-modified -galactosylceramide (-GalCer) analogues is de-
scribed, establishing a chemical platform to comprehensively investigate the structure-activity relationships (SAR) of this 
understudied glycolipid part. The strategy relies on a late-stage reductive ring-opening of a p-methoxybenzylidene (PMP) 
acetal to regioselectively liberate the 4”-OH position. The expediency of this methodology is demonstrated by the synthesis 
of a small yet diverse set of analogues, which were tested for their ability to stimulate invariant natural killer T-cells (iNKT) 
in vitro and in vivo. The introduction of a p-chlorobenzyl ether yielded an analogue with promising immunostimulating 
properties, paving the way for further SAR studies.
For over two decades, -galactosylceramide (-GalCer or 
KRN7000; 1) has been serving as a lead structure for the 
development of new glycosphingolipids targeting the im-
mune system.1-4 -GalCer is a synthetic glycolipid resulting 
from the structural optimization of agelasphins, a class of 
amphiphilic natural products isolated from the marine 
sponge Agelas mauritianus.5,6 It is composed of a polar D-
galactose unit, -anomerically linked to a lipophilic 
ceramide tail. This ceramide, in turn, is built from D-ribo-
phytosphingosine, which is N-acylated at C2’ with cerotic 
acid (hexacosanoic acid). 
-GalCer binds to the major histocompatibility complex 
(MHC) class I-like glycoprotein CD1d, associated with the 
membrane of antigen-presenting cells (APCs).7 This binary 
CD1d-glycolipid complex is presented to the T-cell recep-
tor (TCR) of invariant natural killer T-cells (iNKT cells), 
evoking simultaneous release of T-helper 1 (Th1) and T-
helper 2 (Th2) cytokines.8,9 The pro-inflammatory Th1-cy-
tokines, such as interferon- (IFN-), are involved in anti-
tumor, antiviral and antibacterial effects, whereas the anti-
inflammatory Th2-cytokines, such as interleukin 4 (IL-4), 
counteract the development of autoimmune diseases. 
However, the antagonizing effect of both cytokine types se-
verely hampers clinical potential of -GalCer as an im-
munomodulator. This renders research towards new ana-
logues with an improved immunological profile, slanting 
towards secretion of either Th1- or Th2-cytokines, highly 
relevant. 
 
Figure 1. Structural formula of 1 and some reported 4”-
analogues. 
The list of new -GalCer analogues continues to grow, 
with much attention being devoted to modifications of the 
 
hydroxyl groups of the galactose unit, thereby gradually re-
vealing more of the SAR of this key glycolipid part. Modi-
fications at the 2”-position lead to a complete disappear-
ance of antigenicity, due to abrupt disturbance of a vital 
hydrogen bonding interaction with Gly96 of the TCR.10,11 
A sulfate group can be substituted for the 3”-OH-group.12 
The SAR of the 6”-position has been extensively studied, 
mainly for two reasons. First, the 6”-OH is the only primary 
hydroxyl group of the sugar part, which from a chemose-
lective point of view implies that straightforward modifica-
tion of this position is possible. Indeed, our laboratory has 
already explored the mild yet powerful regioselective ben-
zylidene ring-opening route to access the 6”-position for 
the synthesis of fucosyl, galacturonic acid, triazole, carba-
mate and urea analogues.13-15 Second, and more im-
portantly, this hydroxyl group does allow for modifications 
due to the absence of any major interactions with either 
CD1d or the TCR,16 and this has given rise to an array of 
new immunoactive analogues.17-22 
In contrast to this, only few 4”-analogues of -GalCer are 
known (Figure 1) and, as a consequence, the SAR of this 
position has been poorly investigated. Crystallographic 
studies have shown that the 4”-OH forms a hydrogen bond 
to the main chain carbonyl group of Phe29 of the TCR, 
indicating that it acts as a hydrogen bond donor.16 4”-De-
oxygenation leads to a less active analogue (2) as compared 
to -GalCer, yet recognition by the TCR is not severely dis-
turbed.23 Derivatization of the 4”-OH as O-methyl ether (3) 
or O-ethanol ether (4) gives slightly less potent analogues, 
whereas the N-acetyl analogue (5) is a significantly weaker 
antigen.24 Additionally, a couple of active analogues bear-
ing an aromatic ring on the 4”-position have been synthe-
sized (6-8).25 Inversion of the 4”-OH gives -glucosylcer-
amide (-GlcCer), which is slightly less active as compared 
to -GalCer.7 
Scheme 1. Synthesis of trichloroacetimidate donor 
13.a 
 
aReagents and conditions: (a) p-thiocresol, BF3Et2O, CH2Cl2, 
0 °C (94%); (b) NaOMe, MeOH, rt (quant.); (c) p-anisaldehyde 
dimethylacetal, CSA, CH2Cl2, 4Å MS, rt (87%); (d) NaH, 
PMBCl, TBAI, DMF, 0 °C to rt (98%); (e) NIS, MeCN, H2O, 0 
°C (99%); (f) Cl3CCN, DBU, CH2Cl2, 0 °C (94%). 
To explore the SAR more thoroughly, a reliable and scal-
able synthesis route is highly needed. Here, we present the 
synthesis of two powerful precursors (16 and 19) with a free 
4”-OH, permitting the fast generation of new 4”--GalCer-
analogues in a late stage of the synthesis. This divergent 
strategy uses PMB ethers as hydroxyl protecting groups, in 
contrast to most other syntheses, which use benzyl groups. 
Although they are widely used because of their easy intro-
duction and relative inertness towards a plethora of condi-
tions, benzyl groups suffer from the major drawback that 
by deprotection via catalytic hydrogenolysis some medici-
nally interesting functionalities, such as alkenes, alkynes, 
thioethers, naphthalenes, (iso)quinolines, furans, thio-
phenes, cyclopropanes and chloroarenes, might be (partly) 
reduced. This unavoidably restricts the structural diversity 
of the analogues. PMB ethers, on the other hand, can be 
cleaved under mild and widely tolerated conditions, there-
fore permitting a broader substrate scope.26 
The previously reported trichloroacetimidate donor 
(13)27 was synthesized via an improved scalable route from 
cheap -D-galactose pentaacetate (9) (Scheme 1). Intro-
duction of the p-thiotolyl moiety as an anomeric protecting 
group and subsequent deacetylation under Zemplén con-
ditions was followed by installation of the p-methoxyben-
zylidene acetal and protection of the remaining hydroxyl 
groups as PMB ethers to yield the fully protected interme-
diate 11. Attempts to remove the p-thiotolyl group with N-
iodosuccinimide (NIS) in acetone/H2O 10:1 resulted in par-
tial conversion of the p-methoxybenzylidene acetal to an 
isopropylidene acetal. This inconvenience was overcome 
by performing the reaction in acetonitrile/H2O 10:1, giving 
hemiacetal 12 as a mixture of anomers (: ~ 6:4 at 25 °C in 
CDCl3) in a nearly quantitative yield. Finally, 12 was con-
verted to the corresponding -trichloroacetimidate under 
thermodynamic control, furnishing donor 13 in an overall 
yield of 75% over 6 steps. All intermediates, except for 13, 
can be purified by simple crystallization from a suitable 
solvent system. 
Efforts were undertaken to perform the glycosylation of 
the known acceptor 1428 with the thioglycoside donor 11, as 
this would shorten the synthesis route. However, the ap-
plication of neither benzenesulfinyl morpholine (BSM),29 
nor NIS or copper(II) triflate30 as thiophilic promoters 
proved to be successful. These highly electrophilic condi-
tions, typically used in thioglycosylations,31 were found to 
be incompatible with the p-methoxybenzylidene acetal. In-
deed, p-methoxybenzylidene and p-thiotolyl cleavage were 
observed as the main side reactions. 
Glycosylation was successful at the trichloroacetimidate 
stage through application of the “inverse protocol” 
(Scheme 2).32 By slow addition of donor 13 to a solution of 
acceptor 14 and BF3OEt2 as the promoter at -20 °C, the de-
sired glycoside 15 was obtained as -anomer only in 85% 
yield. The use of trimethylsilyl trifluoromethanesulfonate 
(TMSOTf) as glycosylation promoter led to silylation of the 
acceptor, while the common protocol with BF3OEt2, 
wherein the promoter is added to a solution of donor and 
acceptor, gave the glycoside in lower yields (30-50%) due 
to more extensive decomposition of the donor before gly-
cosylation. The high stereoselectivity observed in this re-
action is caused by a well-known conformational effect ex-
hibited by the 4”,6”-O-acetal, forming a cis-decalin-like 
system with the galactose ring.33 
 
Scheme 2. Glycosylation of 13 with 14 and subsequent 
regioselective ring-opening of glycoside 15.a 
 
aReagents and conditions: (a) 14, BF3Et2O, THF, Et2O, 4Å 
MS, -20 °C (85%); (b) DIBALH, toluene, -80 °C (89%); (c) BaO, 
Ba(OH)2, MeI, DMF, rt (93%). 
Next, attempts were made to regioselectively open the p-
methoxybenzylidene acetal in order to liberate the 4”-OH 
function. Experiments involving BH3THF/Cu(OTf)2,34 
BH3THF/nBu2BOTf35 or PhBCl2/TESH36 as reducing agents 
mainly gave rise to degradation of the p-methoxybenzyli-
dene acetal and the glycosidic bond. A more successful ap-
proach was the use of diisobutylaluminium hydride 
(DIBALH) in toluene,37 while keeping the temperature at -
80 °C to avoid azide reduction (Scheme 2). This afforded 
azido alcohol 16 as a single regioisomer in 89% yield. The 
structure of 16 was unambiguously proven by derivatiza-
tion as the corresponding methyl ether (17) and analysis of 
the relevant cross peaks in the HSQC and HMBC spectra 
(see Supporting Information). 
Scheme 3. Amide formation of 16.a 
 
aReagents and conditions: (a) (i)H2S, pyridine, H2O, rt; (ii)18, 
Et3N, THF, 70 °C (86% over 2 steps). 
Azido alcohol 16 was subjected to azide reduction under 
the classical Staudinger conditions with PMe3, followed by 
EDC-mediated amide formation with hexacosanoic acid 
(cerotic acid). However, it was observed that the interme-
diate iminophosphorane was highly stable and even with 
concentrated sodium hydroxide at elevated temperatures 
its hydrolysis proceeded sluggishly, providing amide 19 in 
a rather low yield (43% over 2 steps). To reduce the azide 
in a more efficient way, we turned our attention to hydro-
gen sulfide in a pyridine/H2O mixture. This readily fur-
nished the amine, which was immediately acylated with N-
succinimidyl hexacosanoate (NSHC, 18) under basic con-
ditions to deliver amide 19 in 86% yield over 2 steps 
(Scheme 3). To drive the reaction to completion within a 
reasonable amount of time, the amide formation was car-
ried out at 70 °C. 
Both 16 and 19 were now suited for late-stage diversifica-
tion. Alkylation of the 4”-OH had to be performed at the 
azide stage, since methylation of 19 with methyl iodide and 
BaO/Ba(OH)2 in DMF yielded an unseparable mixture of 
O- and N-alkylated products in a 4:1 ratio (as determined 
via 1H NMR spectroscopy). Thus, alkylation of 16 with p-
chlorobenzyl bromide gave derivative 22 (Scheme 4). Both 
17 and 22 were subjected to H2S-mediated azide reduction 
and subsequent amide formation. The final PMB ether 
cleavage was performed using HCl in 1,4-dioxane, swiftly 
delivering analogues 21 and 24. Anisole was added in large 
excess (10 equiv.) as a scavenger for the highly reactive p-
methoxybenzyl carbocation. 
Scheme 4. Synthesis of O-alkylated analogues 21 and 
24.a 
 
aReagents and conditions: (a) (i)H2S, pyridine, H2O, rt; (ii)18, 
Et3N, THF, 70 °C (78% over 2 steps); (b) HCl, 1,4-dioxane, ani-
sole, rt (32%); (c) p-chlorobenzyl bromide, BaO, Ba(OH)2, 
DMF, rt (92%); (d) (i)H2S, pyridine, H2O, rt; (ii)18, Et3N, THF, 
70 °C (66% over 2 steps); (e) HCl, 1,4-dioxane, anisole, rt 
(30%). 
Besides alkylation, some other chemistries were explored 
to create a diverse set of analogues (Scheme 5). Car-
bamoylation of 19 with 1-naphthyl isocyanate delivered, af-
ter deprotection, naphthyl carbamate analogue 26. This 
analogue structurally resembles the 6”-naphthyl urea, 
which exerts a strong Th1-bias as a result of the naphthyl 
moiety occupying an additional binding pocket in CD1d.18 
Oxidation of the alcohol in 16 using a Swern oxidation de-
livered the corresponding ketone, which, without interme-
diate purification, smoothly underwent a mild Julia-Ko-
cienski olefination with 1-methyl-2-(methylsulfonyl)-1H-
benzo[d]imidazole (MSBI, 27)38 to give the exocyclic meth-
ylene derivative. Following azide reduction, amide for-
mation and overall deprotection, analogue 29 was ob-
tained. Finally, the OH-group was converted into the cor-
responding azide 30 via a DPPA-mediated Mitsunobu re-
action. The azide was reduced and derivatized as the cor-
responding naphthyl urea, eventually delivering analogue 
32.
 
Scheme 5. Synthesis of naphthyl analogues 26 and 32, and alkenyl compound 29.a 
 
aReagents and conditions: (a) 1-naphthyl isocyanate, DMF, rt (89%); (b) HCl, 1,4-dioxane, anisole, rt (44%); (c) (i)(COCl)2, DMSO, 
Et3N, CH2Cl2, -78 °C; (ii)27, KOtBu, DMF, rt; (iii)H2S, pyridine, H2O, rt; (iv)18, Et3N, THF, 70 °C (61% over 4 steps); (d) HCl, 1,4-dioxane, 
anisole, rt (31%); (e) DPPA, DEAD, PPh3, THF, -20 °C to rt (74%); (f) (i)H2S, pyridine, H2O, rt; (ii)1-naphthyl isocyanate, DMF, rt 
(22% over 2 steps); (g) HCl, 1,4-dioxane, anisole, rt (48%). 
The set of new analogues (21, 24, 26, 29 and 32) was eval-
uated for its immunostimulating capacity, both in vitro and 
in vivo. C57BL/6 mice were injected intraperitoneally with 
the glycolipids (5 µg of each analogue: 10 nM for 24, 26 and 
32, 11 nM for 21 and 29) and the blood serum levels of the 
cytokines were measured by ELISA (Figure 2). IFN- was 
quantified 16 h after injection, whereas IL-4 was measured 
4 h after injection. All of the analogues were able to stimu-
late the immune system, albeit at levels comparable to or 
lower than those elicited by -GalCer (1). Although the 4”-
OH acts as a hydrogen bond donor to interact with the 
TCR, derivatization as a simple ether is allowed. The anti-
genic effect is most dramatic when introducing a methyl 
group (21). The p-chlorobenzyl analogue 24 was found to 
polarize the cytokine response towards Th1, although its 
antigenicity was lower than that of -GalCer. Yet, we be-
lieve that this analogue might be a good lead structure for 
future optimization towards highly potent Th1-polarizing 
-GalCer analogues. 
In the same way, introducing a gluco-naphthyl urea on 
the 4”-position (32) yields an analogue that is Th1-polariz-
ing. Future structural studies might shed light on the 
mechanism underlying this Th1-polarization, but en-
hanced interaction with CD1d may account for this obser-
vation. The galacto-naphthyl carbamate (26), in which the 
naphthyl group is unlikely to interact with CD1d due to its 
axial configuration, is significantly less potent. 
Remarkably, even when no heteroatom is present at C4”, 
as exemplified by the exocyclic alkene (29), immunostim-
ulatory capacity is partly preserved. Apparently, the exocy-
clic alkene, which will partly flatten the galactose ring, in-
duces a pyranose conformation that is still able to bridge 
between CD1d and the TCR. Further structural studies are 
required to gain more insight into this phenomenon. 
 
 
Figure 2. IFN- and IL-4 secretion after intraperitoneal 
injection of 5 µg of each analogues in C57BL/6 mice. 
To assess if these analogues also stimulate human iNKT 
cells, the latter were co-cultured with HeLa CD1d cells with 
varying concentrations of the glycolipids. After 24 h of in-
cubation the IFN- levels were determined by ELISA (Fig-
ure 3). These results reflect the observations in mice, 
namely that all of the compounds are able to stimulate 
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Figure 3. IFN- levels measured upon incubation of dif-
ferent concentrations of the analogues with human iNKT 
and HeLa CD1d cells. 
In summary, we have developed a concise and scalable 
synthetic route towards two valuable precursors (16 and 
19) to perform late-stage diversification of the 4”-OH posi-
tion of -GalCer. In this strategy, a triple role has been pro-
vided for the 4”,6”-O-p-methoxybenzylidene acetal: as a 
protecting group, as a stereocontrolling element during 
glycosylation and as a structural element to enable a regi-
oselective ring-opening. We have demonstrated the utility 
of this method by synthesizing a diverse set of analogues, 
that was tested for the ability to stimulate iNKT cells both 
in vitro an in vivo. In both cases, the analogues were able to 
stimulate iNKT cells, some of them showing a clear pro-
inflammatory activity due to Th1-polarization. Even 
though the 4”-OH is involved in binding to the TCR, we 
have shown that derivatization is allowed, which should 
inspire further biological and structural research to com-
prehensively explore the SAR of this glycolipid part. 
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